We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00293761
First Posted: February 20, 2006
Last Update Posted: November 18, 2016
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Alcon Research
February 17, 2006
February 20, 2006
November 18, 2016
January 2006
May 2006   (Final data collection date for primary outcome measure)
Mean IOP
Not Provided
Complete list of historical versions of study NCT00293761 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
A Study of Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension
Not Provided
The purpose of the study is to determine whether a glaucoma therapy is safe and effective in treating patients with open-angle glaucoma or ocular hypertension
Not Provided
Interventional
Phase 3
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
  • Open-angle Glaucoma
  • Ocular Hypertension
  • Drug: Travoprost, Investigational
    One drop in study eye once daily for 13 days
  • Drug: Travoprost (TRAVATAN)
    One drop in study eye once daily for 13 days
    Other Name: TRAVATAN
  • Experimental: Travatan, Investigational
    Intervention: Drug: Travoprost, Investigational
  • Active Comparator: Travatan
    Intervention: Drug: Travoprost (TRAVATAN)
Gross RL, Peace JH, Smith SE, Walters TR, Dubiner HB, Weiss MJ, Ochsner KI. Duration of IOP reduction with travoprost BAK-free solution. J Glaucoma. 2008 Apr-May;17(3):217-22. doi: 10.1097/IJG.0b013e31815a3472.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
109
May 2006
May 2006   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Adult patients of either sex of any race diagnosed with open-angle glaucoma (with or without pseudoexfoliation or pigment dispersion component) or ocular hypertension.
  • Other protocol-defined inclusion criteria may apply.

Exclusion Criteria:

  • Under age 18.
  • Other protocol-defined exclusion criteria may apply.
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
United States
 
NCT00293761
C-05-51
Not Provided
Not Provided
Not Provided
Alcon Research
Alcon Research
Not Provided
Not Provided
Alcon Research
March 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP